Analyst Downgrades: Valeant Pharmaceuticals Intl Inc, Baidu Inc, and Expedia Inc

Analysts downwardly revised their ratings and price targets on Valeant Pharmaceuticals Intl Inc (VRX), Baidu Inc (ADR) (BIDU), and Expedia Inc (EXPE)

Jul 29, 2016 at 10:35 AM
facebook X logo linkedin

Analysts are weighing in on drugmaker Valeant Pharmaceuticals Intl Inc (NYSE:VRX), China-based tech stock Baidu Inc (ADR) (NASDAQ:BIDU), and travel concern Expedia Inc (NASDAQ:EXPE). Here's a quick roundup of today's bearish brokerage notes on VRX, BIDU, and EXPE.

  • VRX is off 2.8% at $22.49 after Wells Fargo reiterated its "underperform" rating, noting that it does not see signs of a turnaround for the stock -- which has shed more than three-quarters of its value so far in 2016. Despite the shares being stuck firmly below the $25 level for more than a month, options traders have not been shy about picking up bullish bets. Across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Valeant Pharmaceuticals Intl Inc holds a 10-day call/put volume ratio of 3.05 -- just 2 percentage points from an annual high.
  • BIDU received price-target cuts from Piper Jaffray, Brean, and Deutsche Bank, with the former setting the lowest target at $180 -- still a 14.6% premium to the stock's current value. The shares are off 5.2% at $157.03 today following the company's second-quarter earnings results, which included a disappointing current-quarter outlook. Options traders were bearishly aligned heading into earnings, but some short sellers may be wishing they had held out longer. Short interest on Baidu Inc fell by about 29% over the last two reporting periods, and now represents just 2.4% of the stock's total float.
  • EXPE is down 2.9% at $115.79, testing a recent foothold above the $115 level, after the company's quarterly earnings beat estimates, but revenue fell short. Following the report, Expedia Inc received five price-target cuts, in a range from $118 to $160, while two analysts adjusted their price targets higher. The stock has given back 7% year-to-date, and could be in even more trouble should analysts continue to change their tune. At present, 12 out of 17 brokerage firms rate underperforming EXPE a "buy" or better.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI